8-K: Prelude Therapeutics Announces Promising Early Data for CDK9 Inhibitor PRT2527 in Lymphoid Malignancies

Prelude Therapeutics reported encouraging interim results from a Phase 1 trial of PRT2527, a CDK9 inhibitor, showing activity in relapsed/refractory lymphoid malignancies, both as a monotherapy and in combination with zanubrutinib.

Summary

• Prelude Therapeutics presented initial clinical data from its Phase 1 dose-escalation trial of PRT2527, a CDK9 inhibitor, at the American Society of Hematology Annual Meeting.
• The study included 46 patients with relapsed/refractory lymphoid malignancies, with 29 receiving PRT2527 monotherapy and 17 receiving it in combination with zanubrutinib.
• PRT2527 was generally well-tolerated across four monotherapy and three combination therapy dosing cohorts.
• The monotherapy arm showed an overall response rate of 17.4% (4 out of 23 evaluable patients), while the combination arm had an overall response rate of 38.5% (5 out of 13 evaluable patients).
• The most frequent treatment-emergent adverse events were neutropenia (48%) and nausea (33%).
• Five patients discontinued treatment due to adverse events in the monotherapy group, while no discontinuations occurred in the combination group.
• The company plans to seek a partner for further development of PRT2527 in hematologic malignancies, focusing resources on their SMARCA degrader programs.

Sentiment

Score: 7

Explanation: The document presents positive clinical data, particularly for the combination therapy, but the company's decision to seek a partner and focus on other programs introduces some uncertainty. The safety profile is acceptable, but the high rate of neutropenia is a concern.

Positives

• PRT2527 showed promising activity as both a monotherapy and in combination with zanubrutinib.
• The combination therapy demonstrated a notable overall response rate of 38.5%.
• The drug was generally well-tolerated, with most adverse events being manageable.
• The study included patients with prior CAR-T therapy, indicating potential for use in heavily pre-treated populations.
• The company believes the data confirms the potential of CDK9 inhibition as a therapeutic approach for hematologic malignancies.

Negatives

• The monotherapy arm had a lower overall response rate of 17.4%.
• Neutropenia was a frequent adverse event, occurring in 48% of patients.
• Five patients discontinued treatment in the monotherapy arm due to adverse events.
• Dose interruptions due to adverse events occurred in 17 patients.
• One patient experienced a dose-limiting toxicity (DLT) of grade 3 tumor lysis syndrome.

Risks

• The study is still in Phase 1, and further clinical trials are needed to confirm the efficacy and safety of PRT2527.
• The company plans to seek a partner for further development, which may introduce delays or uncertainties.
• The high rate of neutropenia could limit the use of PRT2527 or require careful monitoring and management.
• The company is shifting focus to SMARCA degrader programs, which may reduce resources allocated to the CDK9 program.
• The forward-looking statements are subject to risks and uncertainties, including the ability to advance product candidates and obtain regulatory approvals.

Future Outlook

Prelude Therapeutics plans to seek a partner for the further development of PRT2527 in hematologic malignancies, while focusing internal resources on their SMARCA degrader programs.

Management Comments

• Jane Huang, M.D., President and Chief Medical Officer of Prelude, stated that CDK9 has long been considered a potential therapeutic approach for treating hematologic malignancies and a highly selective CDK9 inhibitor was sought to minimize off target toxicity.
• Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, stated that the clinical data presented today with PRT2527 confirm their hypothesis that a highly selective and potent inhibitor of CDK9 has the potential to offer meaningful clinical activity for patients with hematologic malignancies.

Industry Context

The development of CDK9 inhibitors is a growing area of interest in oncology, particularly for hematologic malignancies. The results from Prelude's trial suggest that PRT2527 could be a competitive option in this space, especially given its selectivity and the combination therapy results. However, the company's decision to seek a partner indicates a strategic shift towards other programs.

Comparison to Industry Standards

• The overall response rate of 38.5% in the combination arm is promising compared to typical response rates for relapsed/refractory lymphoid malignancies, which often range from 20-30% with standard therapies.
• Other companies like Novartis and AbbVie are also exploring CDK9 inhibitors, but the specific selectivity and combination approach of PRT2527 may offer a differentiated profile.
• The safety profile of PRT2527 appears manageable, although neutropenia is a common side effect with this class of drugs, which is consistent with other CDK9 inhibitors in development.
• The inclusion of patients with prior CAR-T therapy is notable, as this population often has limited treatment options, and the response rate in this group is a key differentiator.

Stakeholder Impact

• Shareholders may view the clinical data positively, but the decision to seek a partner for PRT2527 may introduce some uncertainty.
• Patients with relapsed/refractory lymphoid malignancies may benefit from the development of PRT2527.
• Employees may be impacted by the shift in focus towards SMARCA degrader programs.

Next Steps

• Prelude Therapeutics will seek a partner for the further development of PRT2527.
• The company will continue to advance its SMARCA degrader programs.
• The company will continue the ongoing Phase 1 study of PRT2527.

Key Dates

Keywords

PRT2527, CDK9 inhibitor, lymphoid malignancies, zanubrutinib, hematologic cancers, clinical trial, monotherapy, combination therapy, relapsed/refractory, CAR-T therapy, neutropenia, SMARCA degrader